Oxford Global Genome Editing and Transgenic 2017 Boston

  • Conference Call
  • Oxford Global Ltd. is invit­ing you to join the Genome Edit­ing and Trans­genic Con­gress USA 2017, held on May 1011, 2017 in Boston, Mass­a­chu­setts.

    Over 20 pre­sen­ta­tions ded­i­cated to genome edit­ing tech­nolo­gies and the appli­ca­tions of genome edit­ing in a range of ther­a­peu­tic areas, includ­ing mus­cu­lar dys­tro­phy, car­dio­vas­cu­lar dis­eases, genetic dis­or­ders and immunotherapies.

    Includ­ing inter­ac­tive ses­sions focus­ing on:

    • Genome Edit­ing Techniques
    • Ther­a­peu­tic Appli­ca­tions of Genome Editing
    • Drug Dis­cov­ery & Devel­op­ment Applications

    Con­firmed Speakers

    • Wojtek Auer­bach, Senior Direc­tor Embry­onic Stem Cell Tech­nolo­gies – Regeneron
    • James Carothers, Assis­tant Pro­fes­sor of Chem­i­cal Engi­neer­ing – Uni­ver­sity of Washington
    • Zheng-​Yi Chen, Asso­ciate Pro­fes­sor – Har­vard Med­ical School
    • André Choulika, Chief Exec­u­tive Offi­cer – Cellectis
    • George Church, Pro­fes­sor of Genet­ics & Health Sci­ences & Tech­nol­ogy – Har­vard Uni­ver­sity & Mass­a­chu­setts Insti­tute of Tech­nol­ogy (HST)
    • Guru­murthy Channabasava­iah, Direc­tor, Trans­genic Core Facil­ity – Uni­ver­sity of Nebraska Med­ical School
    • Jim Collins, Pro­fes­sor – Mass­a­chu­setts Insti­tute of Technology
    • Lev Fedorov, Direc­tor of OHSU Trans­genic Mouse mod­els Shared Resource – Knight Can­cer Insti­tute at Ore­gon Health & Sci­ence University
    • Nicholas Gale, Senior Direc­tor Ther­a­peu­tic Tar­get Dis­cov­ery – Regeneron
    • Nas­reen Haque, Asso­ciate Pro­fes­sor – New York Med­ical School
    • William Theodorus Hen­driks, Instruc­tor in Neu­rol­ogy Mass­a­chu­setts Gen­eral Hos­pi­tal – Har­vard Med­ical School
    • Rob Howes, Direc­tor, Reagents and Assay Devel­op­ment, Dis­cov­ery Sci­ences – AstraZeneca
    • Sang Yong Kim, Direc­tor of Rodent Genetic Engi­neer­ing Lab­o­ra­tory and Research Asso­ciate Pro­fes­sor – NYU School of Medicine
    • Melissa Lar­son, Tech­ni­cal Direc­tor – Uni­ver­sity of Kansas Med­ical Centre
    • Mar­cello Maresca, Asso­ciate Prin­ci­pal Sci­en­tist – AstraZeneca
    • Danilo Mad­dalo, Prin­ci­pal Sci­en­tist – Novartis
    • John McLaugh­lin, Direc­tor of the Trans­genic and Embry­onic Stem Cell Core Shared Resource and Asso­ciate Pro­fes­sor – Ohio State University
    • Thom Saun­ders, Direc­tor of the Trans­genic Ani­mal Model Core and Research Asso­ciate Pro­fes­sor – Uni­ver­sity of Michigan
    • Toru Takeo, Assis­tant Pro­fes­sor, Divi­sion of Repro­duc­tive Engi­neer­ing, Cen­ter for Ani­mal Resources and Devel­op­ment – Kumamoto University
    • William Velander, Pro­fes­sor – Uni­ver­sity of Nebraska
    • Hart­mut Weiler, Direc­tor Trans­genic Core and Asso­ciate Pro­fes­sor – Med­ical Col­lege of Wisconsin

    Genome Edit­ing: Top­ics and Agenda

    The genome edit­ing mar­ket rep­re­sents a sig­nif­i­cant area of research within the genomic field. Advances in util­is­ing the lat­est CRISPR/​Cas9 and TALEN tech­nolo­gies, novel dis­ease mod­el­ling tech­niques as well as recent key safety and reg­u­la­tory issues all under­pin the vast poten­tial of the market’s suc­cess. In addi­tion to this, experts have high­lighted that the global genome edit­ing mar­ket is expected to reach $5.54 bil­lion by 2021.

    In keep­ing with Oxford Global’s highly suc­cess­ful Genomics and Genet­ics Research series, an expert panel of over 25 speak­ers will present a full con­fer­ence pro­gramme cov­er­ing the top­ics out­lined below:

    Day 1

    Morn­ing Ses­sion – Genome Edit­ing Technologies

    • Comparing/​contrasting dif­fer­ent genome edit­ing tech­nolo­gies: CRISPRs, ZFNs, TAL­ENs, AAVs
    • Novel tech­niques in CRISPR technology
    • Gene acti­va­tion and inhi­bi­tion using dead Cas9
    • Gene deliv­ery sys­tems: viral and non-​viral, nucleic acid, protein

    Stream 1: Drug Dis­cov­ery & Devel­op­ment Applications

    • Achiev­ing edit­ing and con­trol at whole-​genome scale
    • Genome edit­ing approaches to accel­er­ate drug discovery:
      • Tar­get iden­ti­fi­ca­tion, val­i­da­tion and screening
      • Engi­neer­ing ani­mal mod­els for in vivo study
      • Stem cell engi­neer­ing for drug screen­ing and discovery
      • Dis­ease mod­el­ling techniques

    Stream 2: Ther­a­peu­tic Appli­ca­tions of Genome Editing

    Case stud­ies from the areas of:

    • Car­dio­vas­cu­lar diseases
    • Dia­betes
    • Genetic dis­or­ders
    • Cys­tic Fibrosis
    • Can­cer

    Day 2

    Stream 1: Drug Dis­cov­ery & Devel­op­ment Applications

    • Achiev­ing edit­ing and con­trol at whole-​genome scale
    • Genome edit­ing approaches to accel­er­ate drug discovery:
      • Tar­get iden­ti­fi­ca­tion, val­i­da­tion and screening
      • Engi­neer­ing ani­mal mod­els for in vivo study
      • Stem cell engi­neer­ing for drug screen­ing and discovery
      • Dis­ease mod­el­ling techniques

    Stream 2: Ther­a­peu­tic Appli­ca­tions of Genome Editing

    Case stud­ies from the areas of:

    • Car­dio­vas­cu­lar diseases
    • Dia­betes
    • Genetic dis­or­ders
    • Cys­tic Fibrosis
    • Can­cer

    After­noon Ses­sion: Genome Edit­ing Technologies

    • Advanc­ing CRISPR technology
    • Devel­op­ment of deliv­ery solu­tions for genome editing
    • Deliv­ery of dif­fer­ent mod­i­fi­ca­tions: knock­down, knock­out, knockin
    • Soft­ware and bioin­for­mat­ics aspects of genome editing
    • Reg­u­la­tory issues in US genome edit­ing; com­par­i­son to dif­fer­ence reg­u­la­tory guide­lines (US, EU mainly)

    Trans­genic Tech­nolo­gies: Top­ics and Agenda

    Trans­genic tech­nolo­gies for ani­mal mod­els is advanc­ing pro­gres­sively with pio­neer­ing research tak­ing place in the field. The emer­gence of CRISPR/​Cas9 in recent years has become more acces­si­ble to researchers for bet­ter effi­ciency and pre­ci­sion in genetic screen­ing and genome edit­ing of trans­genic models.

    Our inau­gural Trans­genic USA Con­gress will have over 250 del­e­gates rep­re­sent­ing the lead­ing research & aca­d­e­mic insti­tu­tions and clin­i­cal research insti­tu­tions in the USA, as well as lead­ing phar­ma­ceu­ti­cal and biotech com­pa­nies from around the globe.

    Key experts will cover the below topic areas:

    Day 1

    Stream 1: Tech­nol­ogy Workshop

    • Ther­a­peu­tic Appli­ca­tion of Trans­genic Genome Editing
    • Improve­ment of in vivo CRISPR-​Cas genome engineering
    • Novel mouse genome engi­neer­ing tools
    • Mouse trans­ge­n­e­sis: pro­gram­ma­ble nucleases
    • Geno­typ­ing strate­gies and tools

    Stream 2: Tech­nol­ogy Workshop

    • Advances in Ani­mal Biotech­nol­ogy: Dis­cov­ery & Development
    • In vivo CRISPR genetic screen­ing for pre­ci­sion med­i­cine and drug discovery
    • Design­ing the right genes
    • Case stud­ies:
      • Gene edit­ing in pigs
      • Rare genetic disorders

    After­noon Ses­sion: Gen­er­a­tion of Trans­genic Mod­els – Mod­els of Dis­ease and Applications

    • Gen­er­at­ing trans­genic mouse mod­els of neu­rode­gen­er­a­tive diseases
    • Trans­genic rodent and other ani­mal mod­els of diseases
    • Trans­genic mod­els of oncol­ogy, car­dio­vas­cu­lar dis­ease and meta­bolic disorders
    • Organ trans­plan­ta­tion from trans­genic ani­mals into human beings
      • Eth­i­cal considerations
      • Explor­ing reg­u­la­tory pathways

    Day 2

    Morn­ing Ses­sion: Genet­ics, Epi­ge­net­ics, Stem Cell Manipulation

    • Genome and epi­ge­netic edit­ing appli­ca­tions in stem cells
    • Gene reg­u­la­tion and RNA biology
    • Pluripo­tent stem cell-​based dis­ease models
    • Somatic cell nuclear trans­fer (SCNT)
    • Mam­malian syn­thetic biology
    • CRISPR-​Cas genome editing
      • How to reduce the chance of off-​target effects
      • How to reduce the chance of mosaicism

    Stream 1: Ther­a­peu­tic Appli­ca­tion of Trans­genic Genome Editing

    • Cry­op­reser­va­tion of mouse embryos
    • Embryo vit­ri­fi­ca­tion
    • Mouse 3D imag­ing strategies
    • High through­put adult phenotyping
    • Pre­cise tar­geted genome editing

    Stream 2: Novel Trans­genic Technologies

    • Implan­ta­tion and injec­tion systems
    • Repro­gram­ming and trans­d­if­fer­a­tion techniques
    • Recom­bi­na­tion vectors
    • Transposon-​delivered transgenes
    • Plasmid-​based techniques

    Sub­mit a Poster

    For atten­dees inter­ested in sub­mit­ting a poster, there are oppor­tu­ni­ties now avail­able. Your poster pre­sen­ta­tion will be located in the exhi­bi­tion room for two days along­side other posters from those work­ing at the fore­front of Genome Edit­ing research and the Trans­genic field.

    How to sub­mit your abstract

    We will require:

    • Poster title, Abstract (200 words or less)
    • Prin­ci­pal author, Organisation
    • Mail­ing address, Email, Tele­phone, Fax
    • Addi­tional authors

    In order to secure your board space a fee of £250 plus VAT will be required. The poster should be pre­sented as A0 (841mm x 1189mm) por­trait size. To take advan­tage of this oppor­tu­nity you need to be reg­is­tered as a paid del­e­gate over the 2 days. We have lim­ited spaces avail­able, so please reg­is­ter soon!

    starting: ending: 11.05.2017 Location: , Category:

    Timeline

    register now Conference START 11.05.2017 END

    Conference Facts

    Location , Address Avenue Louis Pasteur 77 Category Organiser More Info Conference Website

    Further interesting Conferences

    discover MORE CONFERENCES